[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Biswas G, Laskar S, Banavali SD, Gujral S, Kurkure PA, Muckaden M, Parikh PM, Nair CN: Desmoplastic small round cell tumor: extra abdominal and abdominal presentations and the results of treatment. Indian J Cancer; 2005 Apr-Jun;42(2):78-84
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor: extra abdominal and abdominal presentations and the results of treatment.
  • BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare malignant neoplasm of adolescent males.
  • Current multimodality treatment prolongs life and rarely achieves cure.
  • MATERIALS AND METHODS: Eighteen patients of DSRCT seen during this period were evaluated for their clinical presentation, response to chemotherapy and other multimodality treatment and overall survival.
  • The others, involving chest wall and extremities.
  • RESULTS: The treatment primarily included a multimodality approach using a combination of multiagent chemotherapy with adjuvant surgery and radiotherapy as applicable.
  • A response rate of 39% (CR-1, PR-6), with chemotherapy was observed.
  • The overall response rate after multimodality treatment was 39% (CR-5, PR-2).
  • The overall survival was poor except in patients who had complete excision of the tumor.
  • CONCLUSION: 0 Abdomino-pelvic site was the commonest presentation, the disease can occur at other non-serosal surfaces also.
  • Despite aggressive treatment the outcome was poor.
  • [MeSH-major] Abdominal Neoplasms / therapy. Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. India / epidemiology. Infant. Male. Medical Records. Neoplasm Staging. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16141506.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Suarez CR, Bertolone SJ, Raj AB, Coventry S: Second malignant neoplasms in childhood acute lymphoblastic leukemia: primitive neuroectodermal tumor of the chest wall with germline p53 mutation as a second malignant neoplasm. Am J Hematol; 2004 May;76(1):52-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms in childhood acute lymphoblastic leukemia: primitive neuroectodermal tumor of the chest wall with germline p53 mutation as a second malignant neoplasm.
  • Second malignant neoplasm (SMNs) are a devastating sequelae observed on these children, with an estimated cumulative risk of 2-3.3% fifteen years after diagnosis.
  • Primitive neuroectodermal tumor of bone (PNET) is rarely observed as a SMN following treatment of childhood ALL.
  • The authors described the occurrence of a chest wall PNET of the bone at the site of a central line placement associated with both germ-line and tumor cell p53 mutation in a 8-year-old boy 1 year after completing therapy for standard risk ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Second Primary / genetics. Neuroectodermal Tumors, Primitive, Peripheral / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thoracic Wall / pathology. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Humans. Male. Mutation. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15114597.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


3. Zambrana F, Vicente F, García-Manrique T, Pereira S, Sáinz De Zaitigui J, De La Cruz Merino L: Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy. Clin Transl Oncol; 2010 Mar;12(3):231-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy.
  • Malignant peripheral nerve sheath tumours (MPNST) are a rare variety of soft tissue sarcomas (STS) arising from major peripheral nerve branches and typically located in the lower extremity, chest wall or the retroperitoneum.
  • It is a biologically aggressive neoplasm for which the treatment of choice is surgery, but usually requires a multimodality approach, having been generally labelled as chemoresistant.
  • We present a case of MPNST located intracranially with a good response to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Nerve Sheath Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):601-12 [3559651.001]
  • [Cites] Br J Neurosurg. 1999 Dec;13(6):550-7 [10715722.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):340-9 [18286466.001]
  • [Cites] Am J Dermatopathol. 2000 Jun;22(3):217-29 [10871064.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):23-30 [10469433.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] World J Surg Oncol. 2006 Aug 22;4:55 [16923196.001]
  • (PMID = 20231129.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


Advertisement
4. Huang JH, Fan WJ, Gu YK, Li WQ, Gao F, Li CX, Long H, Yuan YF, Lu LW: [CT-guided percutaneous ethanol ablation in the treatment of malignancies with pleural or chest wall invasion]. Zhonghua Yi Xue Za Zhi; 2008 Dec 23;88(47):3365-8
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CT-guided percutaneous ethanol ablation in the treatment of malignancies with pleural or chest wall invasion].
  • OBJECTIVE: To explore the feasibility and efficiency of CT-guided percutaneous ethanol ablation (PEA) in the treatment of malignant tumors with pleural or chest wall invasion.
  • METHODS: Nine patients of malignant tumors with pleural or chest wall invasion that failed to respond to operation, radiotherapy, or chemotherapy were treated by PEA under CT guidance.
  • The improvement of quality of life (QOL) during the treatment was observed and the efficiency was evaluated by CT scan.
  • PEA was performed successfully 34 times in 18 lesions of these 9 patients.
  • In follow-up, local recurrence and new tumors appeared in 2 patients, but good results were achieved after the second PEA treatment.
  • One tumor came to recurrence in a patient of lung cancer, but it was well controlled after another two times of PEA treatment.
  • One patient with lung cancer gave up treatment and came to recurrence after successful PEA treatment 7 months later.
  • Two patients of primarily hepatocellular carcinoma died of brain metastases 8 and the 9 months after treatment.
  • CONCLUSION: With little damage and few complications, CT-guided PEA is convenient and effective in treatment of malignant tumors with pleural invasion.
  • [MeSH-major] Catheter Ablation / methods. Lung Neoplasms / therapy. Pleura / pathology. Thoracic Wall / pathology
  • [MeSH-minor] Adult. Aged. Ethanol / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19257972.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


5. Yamagami W, Banno K, Kawaguchi M, Yanokura M, Kuwabara Y, Hirao N, Susumu N, Tsukazaki K, Aoki D: Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report. Chemotherapy; 2007;53(2):137-41
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report.
  • BACKGROUND: The collagen gel droplet embedded drug sensitivity test (CD-DST) is a new anticancer drug sensitivity test that only requires a small number of cells.
  • We report the use of this test in the choice of adjuvant chemotherapy for treatment of a rare case of ovarian cancer involving malignant transformation of ovarian mature cystic teratoma.
  • CASE REPORT: The patient was a 70-year-old female with an ovarian tumor, pleural effusion, carcinomatous ascites and a chest wall tumor.
  • The histopathological diagnosis was adenocarcinoma, mature cystic teratoma with malignant transformation, stage IV.
  • Paclitaxel/carboplatin therapy was selected as adjuvant chemotherapy based on CD-DST results.
  • Upon completion of 6 courses, no increases in carcinomatous ascites or recurrent lesions were evident, and the chest wall tumor had disappeared completely.
  • CONCLUSION: The CD-DST may be particularly useful for selecting preoperative chemotherapeutic drugs for patients with ovarian cancer in which the histological type of the primary tumor is unknown.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols. Collagen Type I. Drug Screening Assays, Antitumor. Ovarian Neoplasms / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Female. Gels. Humans. Neoplasm Staging. Paclitaxel / administration & dosage. Pleural Effusion, Malignant

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17308380.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Collagen Type I; 0 / Gels; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Zhang BL, Xu RL, Zheng X, Qin YW: A case with cardiac tamponade as the first sign of primary gastric signet-ring cell carcinoma treated with combination therapy. Med Sci Monit; 2010 Apr;16(4):CS41-44
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case with cardiac tamponade as the first sign of primary gastric signet-ring cell carcinoma treated with combination therapy.
  • CASE REPORT: A 56-year-old woman with emergent dyspnea, anterior chest oppression, and hypotension was diagnosed as having cardiac tamponade due to massive pericardial effusion.
  • The endoscopic examination of the stomach disclosed gastric cancer in the posterior wall of the antrum and the biopsy showed signet-ring cell carcinoma.
  • The gastric cancer was complicated by malignant pericardial effusion and pleural effusion as well as metastasis to the peripheral lymph nodes and bones.
  • The patient was treated with percutaneous pericardiocentesis followed by systemic chemotherapy (oxaliplatin and sequential 5-fluorouracil plus leucovorin).
  • Pericardiocentesis followed by systemic chemotherapy may be effective in controlling such advanced gastric signet-ring cell carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / drug therapy. Cardiac Tamponade / complications. Cardiac Tamponade / diagnosis. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357721.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Hsu PK, Hsu HS, Lee HC, Hsieh CC, Wu YC, Wang LS, Huang BS, Hsu WH, Huang MH: Management of primary chest wall tumors: 14 years' clinical experience. J Chin Med Assoc; 2006 Aug;69(8):377-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary chest wall tumors: 14 years' clinical experience.
  • BACKGROUND: Primary chest wall tumor is rare but it encompasses tumors of various origins.
  • We analyzed our experience with primary chest wall tumors with emphasis on its demographic presentation and management.
  • METHODS: From 1991 to 2004, 62 patients with the diagnosis of primary chest wall tumors were enrolled.
  • Lipoma, chest wall metastasis, direct invasion from nearby malignancy, infection, and inflammation of chest wall were excluded.
  • Malignant and benign tumors were equally distributed.
  • Chondrosarcoma and lymphoma were the 2 most common types of malignant chest wall tumors.
  • Nine of 31 patients (29.0%) with benign chest wall tumors were free of symptoms whereas patients with malignant chest wall tumors were all symptomatic (p = 0.002).
  • A definite diagnosis was obtained in 21 of 26 patients (80.7%) who received nonexcision biopsy.
  • All patients with primary chest wall tumors, except 6 who had medical treatment only, underwent surgical resection.
  • Patients with malignant chest wall tumors were older than those with benign tumors (p < 0.001).
  • The mean largest diameter of tumors was also larger in malignant tumors than in benign tumors (p = 0.04).
  • CONCLUSION: Patients with primary malignant chest wall neoplasm were older than those with benign tumors.
  • The mean size of malignant tumors was larger than that of benign tumors.
  • Adequate surgical resection remains the treatment of choice for patients with primary chest wall tumors.
  • For patients with isolated chest wall lymphoma, surgical resection followed by chemotherapy can be considered to obtain a better outcome.
  • [MeSH-major] Thoracic Neoplasms / therapy. Thoracic Wall

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970274.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


8. Hosoi H, Iehara T, Tsuchiya K, Misawa A, Miyaji M, Yagyu S, Koizumi M, Nishimura T, Tokiwa K, Iwai N, Yanagisawa A, Sugimoto T: Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse. J Pediatr Surg; 2007 Oct;42(10):E9-12
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse.
  • Malignant rhabdoid tumor (MRT) is a highly aggressive tumor that occurs in infancy or childhood.
  • Here we report the long-term survival of a 5-month-old boy with MRT that arose from the chest wall.
  • After total resection of the tumor, the patient was given 4 cycles of doxorubicin, vincristine, and cyclophosphamide, alternating with ifosfamide and etoposide.
  • After 18 months off therapy, he had a local recurrence at the same site.
  • After a second total resection, he was given additional chemotherapy with 30.6-Gy local irradiation.
  • Our experience in this case suggests a fundamental strategy of successful treatment of this highly malignant pediatric tumor:.
  • (1) complete resection of the localized tumor, (2) intensive multiagent chemotherapy for the minimal disseminated disease, and (3) radiotherapy for local control of the disease.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Rhabdoid Tumor / therapy. Salvage Therapy. Thoracic Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Infant. Male. Radiotherapy, Adjuvant. Remission Induction. Survivors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923188.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Handa U, Chhabra S, Mohan H: Aspiration cytology of extramammary tumours metastatic to the breast. Indian J Pathol Microbiol; 2007 Oct;50(4):855-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The metastatic tumors included, 2 cases of malignant melanoma (chest wall and left arm), 1 case each of haematolymphoid malignancy, adenocarcinoma of the ovary, and squamous cell carcinoma (left leg).
  • FNA diagnosis of metastasis to the breast is essential in order to avoid unnecessary mastectomy and to ensure appropriate chemotherapy and/or irradiation treatment.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306588.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


10. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H: Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol; 2007 Dec;64(3):356-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and functional imaging of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive tumor that arises from the pleura and frequently extends to adjacent structures.
  • Major findings include nodular pleural thickening, unilateral pleural effusion, and tumor invasion of adjacent structures.
  • CT tends to underestimate early chest wall invasion and peritoneal involvement and has well-known limitations in the evaluation of lymph node metastases.
  • Because of its excellent contrast resolution, MRI is superior to CT, both in the differentiation of malignant from benign pleural disease, and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion MRI is the most promising technique for the assessment of the tumor microvasculature.
  • In MPM, therapeutic effects of chemotherapy can be monitored with perfusion MRI.
  • It has been shown that FDG-PET is useful for the differentiation of benign from malignant lesions, for staging and monitoring metabolic response to therapy against MPM, and that it has prognostic value.
  • An initial report on PET/CT imaging of MPM has shown increased accuracy of overall staging, improving the assessment of tumor resectability.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging / methods. Neoplasm Staging. Neovascularization, Pathologic / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954021.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 61
  •  go-up   go-down


11. Sato S, Koike T, Yamato Y, Yoshiya K, Motono N, Takeshige M, Homma K, Koizumi N, Yokoyama A, Tsukada H: A case of rapidly growing pulmonary carcinosarcoma. Int J Clin Oncol; 2010 Jun;15(3):319-24
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report herein a case of rapidly growing pulmonary carcinosarcoma, a rare and highly malignant lung neoplasm characterized by a biphasic histopathological pattern consisting of both epithelial and sarcomatous components, and we also summarize the clinical features of this entity based on previously reported cases.
  • A 65-year-old man was referred for further examination of a lung tumor after a routine chest X-ray (CXR) showed a tumor shadow in the right upper lung zone.
  • Chest computed tomography (CT) found a 2.0 cm pulmonary mass with suspected chest wall invasion in the right upper lobe, although cytological evidence of malignancy could not be obtained despite repeated preoperative bronchoscopy.
  • The tumor grew rapidly, indicating the possibility of lung cancer.
  • A right upper lobectomy with chest wall excision was performed.
  • The postoperative definitive diagnosis was carcinosarcoma consisting of adenocarcinoma and chondrosarcoma.
  • The patient subsequently received adjuvant chemotherapy with cisplatin and vinorelbine.
  • Routine follow-up chest CT 7 months after the surgery showed pleural dissemination.
  • Consequently he underwent radiotherapy, but the disseminated tumors enlarged further while he received this treatment.
  • Findings based on previously reported cases and our case suggest that early surgical intervention and combined therapeutic strategy are the most important aspects of treatment for pulmonary carcinosarcoma.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchoscopy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease Progression. Humans. Male. Neoplasm Staging. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / secondary. Pneumonectomy. Tomography, X-Ray Computed. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Mol Pathol. 2008 Sep;17(3):151-8 [18382357.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1514-26 [10584705.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):277-85 [8772780.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):118-27 [8367621.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3893-7 [17094419.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Apr;23(4):461-6 [12694760.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):510-6 [11914631.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):123-36 [7064914.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):691-4 [9275879.001]
  • [Cites] Eur J Cardiothorac Surg. 1996;10(6):403-7 [8817133.001]
  • [Cites] Ann Thorac Surg. 2007 Sep;84(3):973-80 [17720411.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Sep;134(3):619-23 [17723808.001]
  • [Cites] Br J Dis Chest. 1985 Jan;79(1):83-94 [3986115.001]
  • [Cites] Mayo Clin Proc. 1984 Sep;59(9):598-603 [6381913.001]
  • (PMID = 20217450.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


12. Spunt SL, Harper JA, Krasin MJ, Billups CA, Rodriguez-Galindo C: Ewing sarcoma family tumors (ESFT) as second malignant neoplasms (SMN) following treatment of a primary malignant neoplasm (PMN) during childhood. J Clin Oncol; 2004 Jul 15;22(14_suppl):8539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing sarcoma family tumors (ESFT) as second malignant neoplasms (SMN) following treatment of a primary malignant neoplasm (PMN) during childhood.
  • Demographic data, diagnostic and treatment information for both the PMN and SMN, and outcome data were recorded.
  • The median age at diagnosis of PMN was 4.2 years (range, 0.8-12.5 years), and of ESFT was 13.4 years (range, 4.9-22.0 years).
  • The PMN was retinoblastoma (n=3), Wilms tumor (n=2), acute lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma (n=1 each).
  • Six patients received chemotherapy for treatment of the PMN including alkylating agents (n=3), anthracyclines (n=6), and etoposide (n=1).
  • Four also received radiotherapy (RT) for the PMN (dose range, 10.8-48 Gy, median 30 Gy).
  • The ESFT primary sites were chest wall/rib (n=4), extremity (n=3) and pelvis (n=1).
  • CONCLUSIONS: The proportion of ESFT as a SMN following treatment of childhood cancer is similar to the proportion of ESFT as a PMN in childhood.
  • Survival appears to be only slightly inferior to that of de novo ESFT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013834.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Gudena V, Verma N, Post G, Kizziah M, Fenning R, Montero AJ: Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biol Ther; 2008 Jun;7(6):810-3
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
  • Malignant schwannomas or malignant peripheral nerve sheath tumors (MPNST) represent approximately 10% of all soft tissue sarcomas.
  • Metastatic disease from chest wall MPNST is very rare.
  • A 42-year-old female with a prior history of neurofibromas developed MPNST, which later metastasized to the lungs and brain.
  • Studies are ongoing and the results are eagerly awaited regarding the responses to these medications and whether they can positively impact on the natural history of this disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / drug therapy. Neurilemmoma / diagnosis. Neurilemmoma / drug therapy. Pyridines / therapeutic use. Thoracic Wall / pathology
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / therapeutic use. Radiography, Thoracic. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376142.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


14. Inoue C, Kato S, Higuchi K, Inoue H: [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid]. Nihon Kokyuki Gakkai Zasshi; 2007 Mar;45(3):243-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
  • He was admitted because his chest X-ray and CT scan showed atelectasis and a tumor-like region in the right lower lobe of the lung.
  • Serum-CYFRA was 2.8 ng/ml, elevated slightly; however, no other tumor markers for lung cancer were elevated.
  • A diagnosis of squamous cell lung cancer was made based on bronchial washing cytology.
  • Persistent high fever and WBC count elevation did not respond to antibiotics, and reduced only after chemotherapy.
  • The biopsy of the growing tumor in the right lateral abdominal wall revealed carcinoma with sarcomatous component or biphasic-type malignant pleural mesothelioma (MPM).
  • In spite of chemotherapy and radiation therapy for the abdominal wall tumor, the tumor rapidly progressed and the patient died three months after admission.
  • The findings at autopsy suggested the tumor was a sarcomatous MPM.
  • However, immunohistochemical staining and tissue HABP staining revealed biphasic type MPM.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Granulocyte Colony-Stimulating Factor / biosynthesis. Keratins / metabolism. Mesothelioma / metabolism. Pleural Effusion / metabolism. Pleural Neoplasms / metabolism
  • [MeSH-minor] Aged. Antigens, CD44. Biomarkers, Tumor / metabolism. Humans. Keratin-19. Male. Staining and Labeling

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419436.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 68238-35-7 / Keratins
  •  go-up   go-down


15. Huang WR, Li R, Jing Y, Zhang YZ, Wu XX, Gao CJ, Bo J, Yu L, Wang QS, Da WM: [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec;14(6):1146-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
  • Multiple myeloma is a malignant disease with high incidence in middle-aged and old-aged population.
  • This observation is to study the clinical treatment effect of bortezomib in one relapsed multiple myeloma (MM) patient and one primary refractory MM patient.
  • And the disease became further aggressive with 4 courses of chemical therapy regimen including methylprednisolone, Arsenic trioxide, dexamethasone, cyclophosphamide, mitoxantrone, VM-26.
  • Bone destruction became severe, and there was a plasmacytoma about 5 x 6 cm on the patient's right upper chest wall.
  • Therefore, the patient received therapy of bortezomib combined with doxrubicin, dexamethasone and thalidomide (VADT).
  • After one course of therapy with this VADT regimen, IgA in blood plasma decreased from 54 g/L to 6.6 g/L, and abnormal plasma cells in bone marrow decreased from 40% to 0.6%, and plasmacytoma on the patient's right upper chest wall almost absorbed.
  • But there was no obvious clinical effect after the second course of therapy of VADT, and the disease status became progressive again.
  • The second patient was MM patient with a light chain kappa type, III B stage.
  • There was no any effect after two courses of VAD therapy and one course of MOFP therapy.
  • The patient acquired near complete remission after one course of treatment with VADT.
  • And this patient got complete remission after three consecutive VADT therapy.
  • All the side effects could be tolerated and became disappeared after contraposing treatment and stopping the bortezomib regimen therapy.
  • The second patient complicated with severe subacute left hemiplegia after the bortezomib dose had been increased to 1.45 mg/m2 at the third time of the first VADT course and the complication became worst at the following day.
  • Then the condition improved with the support therapy and gradually recovered after two weeks.
  • Therefore, bortezomib is an effective target drug for therapy in refractory multiple myeloma, and more attentions to the side effects should be paid in order to deal with those side effects in time.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204182.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


16. Soumarová R, Seneklová Z, Horová H, Vojkovská H, Horová I, Budíková M, Růzicková J, Jezková B: Retrospective analysis of 25 women with malignant cystosarcoma phyllodes--treatment results. Arch Gynecol Obstet; 2004 May;269(4):278-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of 25 women with malignant cystosarcoma phyllodes--treatment results.
  • PURPOSE: Mastectomy without axillary dissection should be the standard treatment in patients with malignant form of cystosarcoma phyllodes.
  • The role of postoperative radiotherapy and chemotherapy remains to be fully established.
  • We evaluate treatment results in a group of patients with cystosarcoma phyllodes (CP) treated at our Institute.
  • PATIENTS AND METHODS: In this report we analyze treatment outcome in 25 patients with malignant cystosarcoma phyllodes treated at Masaryk Memorial Cancer Institute between 1970 and 1995.
  • Mean tumor size was 10 cm in diameter.
  • Subsequently, 17 patients (68%) received radiotherapy on the breast or chest wall.
  • Time to local relapse after surgery was 4-11 months.
  • CONCLUSION: A specific protocol for the treatment of cystosarcoma phyllodes is missing, probably due to rarity of the disease.
  • The treatment of local recurrent disease remains unsuccessful in most CP patients.
  • We recommend postoperative irradiation on the chest wall in patients with malignant form of CP, because adjuvant radiotherapy decreased the incidence of local relapse in our group of patients.
  • [MeSH-major] Breast Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Phyllodes Tumor / epidemiology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Czech Republic / epidemiology. Disease-Free Survival. Female. Humans. Medical Records. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15205980.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • Twenty percent of patients with late recurrence had a nonteratomatous germ cell tumor other than yolk sac tumor, either alone, with yolk sac tumor, or with a "nongerm cell malignant tumor."
  • Most of these nonteratomatous germ cell tumors other than yolk sac tumor were embryonal carcinoma, although rarely seminoma and choriocarcinoma were encountered.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Late recurrences were seen in many different sites in these patients, including the retroperitoneum, abdomen, pelvis, liver, mediastinum, lung, bone (femur, vertebra, and rib), lymph nodes outside the retroperitoneum and mediastinum (supraclavicular, neck, and axillary regions), scrotum and inguinal regions, adrenal gland, chest wall, and buttocks.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-major] Germinoma / pathology. Neoplasm Recurrence, Local / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. Zielinski M, Hauer J, Hauer L, Pankowski J, Nabialek T, Szlubowski A: Staging algorithm for diffuse malignant pleural mesothelioma. Interact Cardiovasc Thorac Surg; 2010 Feb;10(2):185-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging algorithm for diffuse malignant pleural mesothelioma.
  • An algorithm of preoperative mediastinal nodal staging with endobronchial/endoesophageal ultrasonography (EBUS/EUS) and transcervical extended mediastinal lymphadenectomy (TEMLA) combined with laparoscopy/peritoneal lavage and cytology was analyzed to establish the realistic criteria for radical multimodality treatment of malignant pleural mesothelioma (MPM).
  • The algorithm included computed tomography (CT), thoracoscopy with multiple pleural biopsies and talc pleurodesis, EBUS/EUS and one-stage TEMLA and laparoscopy/peritoneal lavage and cytology of the fluid.
  • There were 16 women and 26 men in ages ranging from 43 to 77 years (mean 57.8); 31 epithelioid, 2 sarcomatoid and 9 biphasic type MPM.
  • 21/42 patients were considered possible candidates for multimodality treatment.
  • Three patients who received neoadjuvant chemotherapy were excluded from this study.
  • Finally, 4/42 (9.5%) patients underwent thoracotomy with one exploration (chest wall infiltration) and three pleuropneumonectomies with the subsequent chemo- and radiotherapy.
  • [MeSH-major] Algorithms. Mesothelioma / diagnosis. Neoplasm Staging / methods. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy. Chemotherapy, Adjuvant. Endosonography. Female. Humans. Laparoscopy. Lymph Node Excision. Lymphatic Metastasis. Male. Medical Futility. Middle Aged. Patient Selection. Peritoneal Lavage. Pleurodesis. Predictive Value of Tests. Radiotherapy, Adjuvant. Thoracoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843550.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Baran JL, Magro CM, King MA, Williams TE Jr, Ross P Jr: Atypical thymoma: a report of seven patients. Ann Thorac Surg; 2004 Aug;78(2):411-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the opposite spectrum are thymic carcinomas; the cell of origin while similar is malignant.
  • METHODS: Seven patients with a diagnosis of atypical thymoma were encountered over a 6-year period from the patient files of the cardiothoracic division of The Ohio State Medical Center.
  • RESULTS: In all patients there was gross or light microscopic invasive disease with involvement of the capsule, phrenic nerve, diaphragm, chest wall, and lung.
  • Surgical extirpation/de-bulking along with radiation therapy in six and chemotherapy in one led to complete disease regression.
  • Intrathoracic recurrences developed in 4 involving lung, pleura, chest wall and diaphragm.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Vessels / pathology. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diaphragm / pathology. Doxorubicin / administration & dosage. Female. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Pericardium / pathology. Phrenic Nerve / pathology. Pleura / pathology. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Thoracic Wall / pathology. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15276487.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 39
  •  go-up   go-down


20. Krüger M, Uschinsky K, Engelmann C: [Surgical treatment of malignant thoracic schwannomas]. Zentralbl Chir; 2001 Mar;126(3):223-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of malignant thoracic schwannomas].
  • [Transliterated title] Chirurgische Therapie thorakaler maligner Schwannome.
  • The objective of this study is to evaluate the results after surgical treatment of malignant tumors arising from the peripheral nerves of the thorax under consideration of adjuvant therapy modalities.
  • PATIENTS AND METHODS: Between 1988 and 1998, 9 patients (6 males, 3 females) underwent surgical treatment for MTNSO and 35 pts. for benign neurogenic tumors.
  • The mean age in patients with malignant tumors was 45 years (range, 25 to 73 years).
  • RESULTS: In patients with MTNSO partial chest wall resections (n = 4) including sternectomy (n = 1), lung resections (n = 2), paravertebral (n = 1) and mediastinal tumor resection (n = 1) and palliative resection of pleural recurrence (n = 1) were performed.
  • Adjuvant therapy was performed in two pts. (adjuvant radiotherapy/chemotherapy for metastatic disease n = 1; adjuvant chemotherapy/adjuvant radiotherapy after resection of recurrent tumor n = 1).
  • Three pts. died 8, 9 and 26 months after the primary surgical procedure.
  • CONCLUSION: Patients with MTNSO have an unfavourable prognosis and local recurrence is frequent even after radical surgical therapy.
  • Therefore an adjuvant treatment in these patients may be justified, even if the value of these therapy modalities is not proved yet.
  • A tumor-free long-term survival especially after complete surgical resection is possible in selected cases.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care. Prognosis. Radiotherapy, Adjuvant. Sternum / surgery. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11301889.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Opitz I, Lardinois D, Arni S, Hillinger S, Vogt P, Odermatt B, Rousson V, Weder W: Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. Eur J Cardiothorac Surg; 2007 May;31(5):773-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
  • OBJECTIVE: Local recurrence remains a major problem in the treatment of malignant pleural mesothelioma.
  • The aim of the underlying study was to establish a standardised local recurrence model in rats which enables to study different intrapleural therapies.
  • MATERIALS AND METHODS: Fifty microlitre containing 1 x 10(6) cells of a syngeneic rat malignant mesothelioma cell line (II-45), established from mesothelioma in Fischer 344 rats exposed to asbestos, were inoculated subpleurally via a left-sided thoracotomy.
  • Evaluation of recurrence at the resection site was performed after 10 days (n=6) and 6 days (n=6).
  • In a second experiment, this new recurrence model was evaluated for the effect of intrapleural therapy with different agents: 4 ml of cisplatin-solution (100mg(2)/kg BW), cisplatin combined with the fibrin-based sealant Vivostat, 4 ml taurolidine 2%, repeated injection of 1 microg of the chemokine CCL-19 at the tumour site and 4 ml povidone-iodine in a dilution 1:10.
  • In a control group, the chest cavity was filled with 4 ml 0.9% NaCl.
  • RESULTS: Six days after inoculation, all animals presented a standardised tumour nodule at the injection site of a mean diameter of 5.1 (+/-0.8)mm.
  • Evaluation of the recurrence after 10 days showed a relapse directly at the resection site, but additional tumour nodules on the ipsi- and contralateral chest wall were found and histologically confirmed.
  • The animals that were sacrificed 6 days after resection of the tumour nodule showed a recurrence only at the resection site with no macroscopic or microscopic evidence of other tumour.
  • CONCLUSIONS: With this new recurrence model for investigation of malignant pleural mesothelioma in rats, we were able to investigate new intrapleural therapies after pneumonectomy.
  • [MeSH-major] Disease Models, Animal. Mesothelioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Animals. Anti-Infective Agents, Local / therapeutic use. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Chemokine CCL19. Chemokines, CC / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy / methods. Fibrin Tissue Adhesive / therapeutic use. Male. Pneumonectomy / methods. Povidone-Iodine / therapeutic use. Rats. Rats, Inbred F344. Taurine / analogs & derivatives. Taurine / therapeutic use. Thiadiazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Povidone-iodine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350855.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Antineoplastic Agents; 0 / Chemokine CCL19; 0 / Chemokines, CC; 0 / Fibrin Tissue Adhesive; 0 / Thiadiazines; 1EQV5MLY3D / Taurine; 25655-41-8 / Povidone-Iodine; 8OBZ1M4V3V / taurolidine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Kang CH, Kim YT, Jeon SH, Sung SW, Kim JH: Surgical treatment of malignant mediastinal neurogenic tumors in children. Eur J Cardiothorac Surg; 2007 Apr;31(4):725-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of malignant mediastinal neurogenic tumors in children.
  • INTRODUCTION: The aim of this study was to identify the role of surgical resection in the treatment of malignant mediastinal neurogenic tumors in children.
  • MATERIALS AND METHODS: Thirty-eight consecutive children, who underwent surgical resection of a malignant mediastinal neurogenic tumor between 1986 and 2004, were included in this study.
  • The tumor cell types were neuroblastoma in 23 patients (60.5%), ganglioneuroblastoma in 14 (36.8%), and malignant neuroepithelioma in 1 (2.6%).
  • Surgery was performed for curative resection in localized tumors and salvage resection of residual mediastinal masses after chemotherapy in stage IV tumors.
  • Adjacent structure invasion was found in eight patients (21.1%), invasion of chest wall in four, heart and vena cava in two, lung in one, and chest wall and lung in one.
  • The 5-year survival was 95.2% for a localized tumor and 52.5% for a stage IV tumor (p=0.004).
  • The significant risk factors of long-term survival were adjacent structure invasion (p=0.002) and a stage IV tumor (p=0.002) by multivariate Cox regression analysis.
  • CONCLUSIONS: Surgical resection of localized malignant mediastinal neurogenic tumor in children showed good long-term survival, and salvage operations after chemotherapy showed acceptable long-term survival.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Ganglioneuroblastoma / mortality. Ganglioneuroblastoma / surgery. Humans. Infant. Infant, Newborn. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Neuroblastoma / mortality. Neuroblastoma / surgery. Postoperative Complications. Preoperative Care / methods. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306984.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Jung JI, Kim HH, Park SH, Song SW, Chung MH, Kim HS, Kim KJ, Ahn MI, Seo SB, Hahn ST: Thoracic manifestations of breast cancer and its therapy. Radiographics; 2004 Sep-Oct;24(5):1269-85
MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic manifestations of breast cancer and its therapy.
  • In most patients, imaging demonstrates thoracic changes resulting from either treatment, complications of treatment, or tumor recurrence or metastasis.
  • The postsurgical imaging appearance of the chest wall depends on the surgical method used (radical mastectomy, modified radical mastectomy, breast-conserving surgery, breast reconstruction).
  • Radiation therapy frequently causes radiation pneumonitis, which occurs approximately 4-12 weeks after the completion of therapy and is characteristically limited to the field of irradiation.
  • Chemotherapy-related complications include cardiotoxicity, pneumonitis, and infection.
  • Ultrasonography and computed tomography are more sensitive than physical examination for detecting local and regional recurrence.
  • The thorax is a common site of metastasis, which may affect the lymph nodes, bone, lung, pleura, or heart and pericardium.
  • Bone metastasis is usually evaluated with bone scintigraphy and may cause spinal cord compression, a serious complication that requires early diagnosis.
  • Familiarity with the spectrum of radiologic findings in breast cancer patients allows accurate image interpretation and correct diagnosis.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Artifacts. Female. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis / radiography. Mammaplasty. Mastectomy / adverse effects. Mastectomy / methods. Middle Aged. Neoplasm Recurrence, Local / radiography. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / radiography. Pneumonia / chemically induced. Pneumonia / radiography. Postoperative Complications / etiology. Postoperative Complications / radiography. Radiation Injuries / radiography. Radiotherapy / adverse effects. Seroma / radiography. Spinal Cord Compression / etiology. Spinal Cord Compression / radiography. Spinal Neoplasms / radiography. Spinal Neoplasms / secondary. Thoracic Neoplasms / radiography. Thoracic Neoplasms / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2004
  • [ErratumIn] Radiographics. 2004 Nov-Dec;24(6):1610
  • (PMID = 15371608.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


24. Sitole S, Zender CA, Ahmad AZ, Hammadeh R, Petruzzelli GJ: Lacrimal sac melanoma. Ophthal Plast Reconstr Surg; 2007 Sep-Oct;23(5):417-9
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT revealed a nonenhancing soft tissue mass of the left lacrimal sac with widening and erosion of the nasolacrimal canal.
  • The tumor was resected and pathologically confirmed to be malignant melanoma.
  • Despite wide resection and adjuvant radiotherapy, the patient developed metastases to the chest wall.
  • The patient currently is receiving combined immunotherapy and chemotherapy.
  • The clinical course and treatment strategies are reviewed for this highly aggressive and rare neoplasm.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Proteins / analysis. Positron-Emission Tomography. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882000.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


25. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • A Wilms' tumor (WT) was present in 73 children.
  • High-risk WT were diagnosed in 12 of 63 patients (19%) (NB with anaplasia 10, clear cell sarcoma 1, malignant rhabdoid tumor 1).
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • In 3 patients preoperative diagnosis by means of imaging failed.
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • Long-term morbidity was analysed in 49 patients and included radiation-induced scoliosis (35), chest-wall deformity (3), congestive cardiomyopathy after relapse (1) and arterial hypertension (2).
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Kara P, Ugur I, Misirlioglu C, Kücükplakci B, Ozgen A, Elgin Y, Demirkasimoglu T, Sanri E: Prevention of malignant seeding at drain sites by hypofractionated radiotherapy in patients with pleural mesothelioma. Asia Pac J Clin Oncol; 2010 Sep;6(3):187-90
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of malignant seeding at drain sites by hypofractionated radiotherapy in patients with pleural mesothelioma.
  • AIM: Unlike most other malignancies, malignant pleural mesothelioma (MPM) has a tendency to recur along tracks of chest wall instrumentation.
  • We investigated the efficiency of hypofractionated radiotherapy for prevention of malignant seeding.
  • METHODS: Twenty-one (six female, 15 male) patients diagnosed with pleural mesothelioma who had chest wall instrumentation and were treated with prophylactic radiotherapy were investigated retrospectively.
  • All patients underwent surgery or thoracoscopy and/or talc pleurodesis, for diagnosis, staging procedures or as a treatment.
  • All were treated with electron (12 MeV) external beam radiation therapy (21 Gy in three fractions over 3 days), directed to the instrumentation pathway after the invasive procedure.
  • After completion of radiotherapy, four of 21 patients had also undergone chemotherapy.
  • None of the followed patients had tumor progression in the treated area.
  • The most common side-effect was grade 1 erythema (Radiation Therapy Oncology Group [RTOG] scale), noted in 13 treated patients.
  • CONCLUSION: Our experience showed that prophylactic radiotherapy to prevent malignant seeding in malignant mesothelioma at invasive procedure sites was effective and well tolerated in preventing malignant seeding, painful metastases after surgery or instrumentation in patients with pleural mesothelioma.
  • Larger multicenter prospective trials are still needed to validate this treatment approach utility for it to be recommended routinely.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / radiotherapy. Neoplasm Seeding. Pleural Neoplasms / pathology. Pleural Neoplasms / radiotherapy. Thoracoscopy / adverse effects
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Drainage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887499.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


27. Malpica A, Deavers MT, Gershenson D, Tortolero-Luna G, Silva EG: Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential. Am J Surg Pathol; 2001 Aug;25(8):988-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential.
  • The involvement of extra-abdominal/extra-pelvic sites by serous tumors after the diagnosis of an ovarian serous neoplasm of low malignant potential is extremely rare.
  • Ten patients also received adjuvant therapy (radiotherapy, 2; chemotherapy and radiotherapy, 4; chemotherapy, 3; intraperitoneal 32P, 1).
  • The interval between the diagnosis of the ovarian neoplasm and the subsequent tumor involving an extra-abdominal/extra-pelvic site ranged from 4 to 240 months (mean 124 months).
  • Sites of extra-abdominal/extra-pelvic involvement and the number of cases were as follows: left neck lymph nodes (LNs), 4; left and right neck LNs, 1; pleura, 2; lung, 1; mediastinum, 1; chest wall, 1; axillary and chest LNs, 1; and vertebral body, 1.
  • Eight patients were treated with chemotherapy, 1 with radiotherapy, 2 with chemotherapy and radiotherapy, and 1 with surgery alone.
  • In this small series of cases, no definitive clinical or pathologic feature related to the occurrence of extra-abdominal/extra-pelvic serous tumors was found.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474282.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Suehara Y, Yazawa Y, Hitachi K, Terakado A: Clear cell sarcoma arising from the chest wall: a case report. J Orthop Sci; 2004;9(2):171-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma arising from the chest wall: a case report.
  • Clear cell sarcoma is a rare malignant soft tissue neoplasm that usually arises adjacent to tendons or aponeuroses.
  • The principal sites of this neoplasm are the extremities, but tumors do occur in the trunk on rare occasions.
  • We report a case of clear cell sarcoma arising from the chest wall.
  • The patient, a 20-year-old woman, had noticed a chest wall mass and pain for 2 years.
  • On immunohistochemical examination, tumor cells were strongly immunoreactive for S-100 and HMB-45.
  • A diagnosis of clear cell sarcoma was confirmed.
  • She was treated with two courses of chemotherapy using ifosfamide, carboplatin, and etoposide.
  • Subsequently, the tumor, including adjacent tissue, the chest wall, and sternum, was resected with a wide margin; and the defect of the chest wall was covered with Marlex mesh fabric, regin, and a musculocutaneous flap.
  • [MeSH-major] Sarcoma, Clear Cell / diagnosis. Soft Tissue Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis. Thoracic Wall

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045547.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Krieghoff B, Skuballa A, Leonhardt P, Mohr FW, Wittekind C, Bossert T, Achatzy R: [Primary synovial sarcoma of the lung - a rare tumor]. Zentralbl Chir; 2002 Aug;127(8):716-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary synovial sarcoma of the lung - a rare tumor].
  • We present a 26 year old patient with a primary malignant synovial sarcoma of the lung that was observed for more than one year by a general practitioner and a pulmologist.
  • Finally, because of recurrent hemoptysis a central tumor of mesenchymal origin of the left lower lobe was diagnosed by bronchoscopy.
  • In the postoperative course the patient underwent chemo-therapy, 6 cycles adriablastine/ifosfamid.
  • 8 months after the first operation an extensive tumor recurrency occurred with infiltration of the chest wall.
  • The patient refused further radio- or chemotherapy and died 14 months after the operation.
  • Because of the small number of cases therapeutic strategy conceptions do not exist.
  • The resection of the tumor is generally recommended.
  • Chemo- and radiotherapy are accepted as an option for advanced tumor stage.
  • [MeSH-minor] Adult. Bronchoscopy. Diagnosis, Differential. Diagnostic Imaging. Humans. Lung / pathology. Male. Neoplasm Staging. Pneumonectomy

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12200737.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Attanoos RL, Gibbs AR: The pathology associated with therapeutic procedures in malignant mesothelioma. Histopathology; 2004 Oct;45(4):393-7
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology associated with therapeutic procedures in malignant mesothelioma.
  • AIMS: To describe iatrogenic pathological lesions in malignant pleural mesothelioma.
  • METHODS AND RESULTS: All cases of malignant pleural mesothelioma confirmed by antemortem pleural biopsy and undergoing post mortem examination over a 7-year period (1995-2001) formed the study group.
  • This comprised 48 malignant pleural mesotheliomas [epithelioid (n = 21), biphasic (n = 14) and sarcomatoid (n = 13)].
  • Twenty-eight of 48 (58%) had received chemical (talc) pleurodesis, 30/48 (63%) palliative localized radiotherapy, 6/48 (13%) chemotherapy, and 14/48 (30%) surgery [12/48 (26%) pleural decortication and 2/48 (4%) pleuropneumonectomy].
  • CONCLUSIONS: Talc pleurodesis induces a marked pseudosarcomatous fibroblastic proliferation which may impart a biphasic pattern to the neoplasm.
  • In 6/8 (75%) of these cases, comparative assessment of the locally irradiated subcutaneous chest wall tumour, with background pleural mesothelioma, showed no morphological difference in architectural tumour growth pattern, extent of necrosis, cytological or nuclear pleomorphism, mitotic activity or tumour immunophenotype.
  • All six malignant pleural mesotheliomas receiving chemotherapy appeared refractory to treatment in that chemotherapy did not appear to have any significant effect on the tumour morphology, cytonuclear pleomorphism, mitotic activity, extent of necrosis or immunophenotype.
  • In the 12 decortication specimens and two pleuropneumonectomy resections, post mortem examination identified evidence of residual malignant mesothelioma of similar morphological subtype and immunophenotype to the resected tumour.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pleurodesis. Radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Iatrogenic Disease. Talc / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15469478.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down






Advertisement